Medipharm Labs Corp (LABS) - Total Assets
Based on the latest financial reports, Medipharm Labs Corp (LABS) holds total assets worth CA$43.62 Million CAD (≈ $31.55 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore LABS operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Medipharm Labs Corp - Total Assets Trend (2016–2025)
This chart illustrates how Medipharm Labs Corp's total assets have evolved over time, based on quarterly financial data. See Medipharm Labs Corp shareholders equity for net asset value and shareholders' equity analysis.
Medipharm Labs Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Medipharm Labs Corp's total assets of CA$43.62 Million consist of 60.1% current assets and 40.0% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$10.81 Million | 23.6% |
| Accounts Receivable | CA$7.53 Million | 16.5% |
| Inventory | CA$8.02 Million | 17.5% |
| Property, Plant & Equipment | CA$17.60 Million | 38.5% |
| Intangible Assets | CA$675.00K | 1.5% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Medipharm Labs Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Medipharm Labs Corp market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medipharm Labs Corp's current assets represent 60.1% of total assets in 2025, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 23.6% of total assets in 2025, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 38.5% of total assets.
Medipharm Labs Corp Competitors by Total Assets
Key competitors of Medipharm Labs Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM
|
India | Rs202.87 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.64 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
|
China | CN¥1.41 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
Medipharm Labs Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.02 | 3.61 | 5.11 |
| Quick Ratio | 2.03 | 2.41 | 4.37 |
| Cash Ratio | 0.00 | 0.96 | 2.11 |
| Working Capital | CA$17.21 Million | CA$23.00 Million | CA$75.63 Million |
Medipharm Labs Corp - Advanced Valuation Insights
This section examines the relationship between Medipharm Labs Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | -14.9% |
| Total Assets | CA$45.74 Million |
| Market Capitalization | $23.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medipharm Labs Corp's assets below their book value (0.50x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medipharm Labs Corp's assets decreased by 14.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medipharm Labs Corp (2016–2025)
The table below shows the annual total assets of Medipharm Labs Corp from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$45.74 Million ≈ $33.09 Million |
-14.87% |
| 2024-12-31 | CA$53.73 Million ≈ $38.87 Million |
-15.96% |
| 2023-12-31 | CA$63.94 Million ≈ $46.25 Million |
-2.38% |
| 2022-12-31 | CA$65.50 Million ≈ $47.38 Million |
-29.09% |
| 2021-12-31 | CA$92.36 Million ≈ $66.81 Million |
-21.88% |
| 2020-12-31 | CA$118.23 Million ≈ $85.53 Million |
-29.97% |
| 2019-12-31 | CA$168.83 Million ≈ $122.13 Million |
+295.12% |
| 2018-12-31 | CA$42.73 Million ≈ $30.91 Million |
+10582.25% |
| 2017-12-31 | CA$400.00K ≈ $289.35K |
+52.56% |
| 2016-12-31 | CA$262.19K ≈ $189.66K |
-- |
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It a… Read more